HC Wainwright Boosts Earnings Estimates for Delcath Systems

Delcath Systems, Inc. (NASDAQ:DCTH) – Equities research analysts at HC Wainwright boosted their Q3 2026 earnings estimates for Delcath Systems in a research note issued to investors on Friday, August 7th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.10) per share for the quarter, up from their prior forecast of ($0.29). HC Wainwright currently has a “Buy” rating and a $32.00 target price on the stock. The consensus estimate for Delcath Systems’ current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Delcath Systems’ Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.17) EPS, FY2027 earnings at $0.12 EPS, FY2028 earnings at $0.56 EPS, FY2029 earnings at $0.97 EPS and FY2030 earnings at $1.46 EPS.

Other analysts have also recently issued reports about the company. Zacks Research raised Delcath Systems from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Wall Street Zen raised Delcath Systems from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings reiterated a “sell (d+)” rating on shares of Delcath Systems in a research report on Friday. Finally, BTIG Research raised their target price on Delcath Systems from $17.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $23.17.

Delcath Systems Trading Up 10.3%

NASDAQ DCTH opened at $16.67 on Tuesday. The stock has a market capitalization of $578.45 million, a price-to-earnings ratio of 1,668.67 and a beta of 0.52. The business’s 50 day moving average is $12.48 and its two-hundred day moving average is $10.92. Delcath Systems has a 12-month low of $8.12 and a 12-month high of $16.69.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.16. Delcath Systems had a net margin of 0.56% and a return on equity of 0.46%. The firm had revenue of $29.13 million during the quarter, compared to the consensus estimate of $26.25 million.

Institutional Investors Weigh In On Delcath Systems

Several institutional investors and hedge funds have recently made changes to their positions in the business. Rosalind Advisors Inc. increased its holdings in Delcath Systems by 13.8% during the 2nd quarter. Rosalind Advisors Inc. now owns 3,300,389 shares of the company’s stock valued at $44,885,000 after acquiring an additional 400,000 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Delcath Systems by 2.9% in the third quarter. Vanguard Group Inc. now owns 1,657,428 shares of the company’s stock valued at $17,817,000 after purchasing an additional 46,693 shares in the last quarter. Nantahala Capital Management LLC purchased a new stake in shares of Delcath Systems in the third quarter valued at about $7,164,000. Goldman Sachs Group Inc. lifted its holdings in shares of Delcath Systems by 116.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 587,678 shares of the company’s stock valued at $5,936,000 after purchasing an additional 315,583 shares in the last quarter. Finally, ExodusPoint Capital Management LP grew its position in shares of Delcath Systems by 30.9% in the fourth quarter. ExodusPoint Capital Management LP now owns 496,705 shares of the company’s stock valued at $5,017,000 after purchasing an additional 117,122 shares during the last quarter. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.